News

Filter

1 to 9 of 10 results

EU Commission fines Lundbeck and other Pharmas over "pay-for-delay" deals

19-06-2013

In a much awaited decision following its investigations of patent settlements (or pay-for-delay deals)…

ActaviscitalopramEuropeFinancialGenericsLegalLundbeckMerck KGaAMylan LaboratoriesNeurologicalPatentsPharmaceuticalRanbaxy Laboratories

Daiichi Sankyo sets out five-year plan to overcome Olmetec patent expiry

25-03-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) has announced a new five-year Business Plan, which will…

Daiichi SankyoFinancialolmesartanOlmetecPatentsPharmaceuticalRanbaxy Laboratories

Ranbaxy in deal with Alembic to market bioequivalent Pristiq in USA

05-03-2013

The US subsidiary of India's largest drugmaker, Ranbaxy Laboratories (AB: BO), which is majority owned…

Alembic PharmaceuticalsDaiichi SankyoGenericsLicensingMarkets & MarketingNeurologicalNorth AmericaPatentsPfizerPristiqRanbaxy Laboratories

Ring in generics in 2012 and beyond, says Zacks Equity Research

03-01-2012

The New Year is expected to be a happy beginning for generic companies like Teva Pharmaceuticals (Nasdaq:…

Dr Reddy's LaboratoriesGenericsMarkets & MarketingNorth AmericaPatentsRanbaxy LaboratoriesSandozTeva Pharmaceutical IndustriesWatson Pharmaceuticals

US launch of generic Lipitor confirms value of competition, says GPhA

01-12-2011

Commenting on this week’s US roll out for generic copies of Pfizer blockbuster cholesterol lowerer…

GenericsLipitorMarkets & MarketingNorth AmericaPatentsPfizerRanbaxy LaboratoriesWatson Pharmaceuticals

Takeda settles Actos patent law suits with Mylan, Watson and Ranbaxy, as well as Teva and others

22-12-2010

Japan’s largest drugmaker, Takeda Pharmaceutical (TYO: 4502), and its US subsidiary have completed…

DiabetesGenericsLegalMylan LaboratoriesPatentsRanbaxy LaboratoriesTakeda PharmaceuticalsTeva Pharmaceutical IndustriesWatson Pharmaceuticals

Outlook for generic equivalent of Pfizer’s Lipitor; how will US exclusivity resolve? asks law firm HPM

14-10-2010

2011 is shaping up to be an interesting year in the Hatch-Waxman world, and all eyes seem to be focusing…

AriceptatorvastatinCardio-vascularFlomaxGenericsLipitorNorth AmericaPatentsPfizerPharmaceuticalRanbaxy LaboratoriesRegulation

1 to 9 of 10 results

COMPANY SPOTLIGHT

Menarini

Back to top